|
KMID : 1144320130450040367
|
|
감염과 화학요법
2013 Volume.45 No. 4 p.367 ~ p.374
|
|
|
Medical Treatment of Pulmonary Multidrug-Resistant Tuberculosis
|
|
Shim Tae-Sun
Jo Kyung-Wook
|
|
|
Abstract
|
|
|
|
Treatment of multidrug-resistant tuberculosis (MDR-TB) is challenging because of the high toxicity of second-line drugs and the longer treatment duration required compared with drug-susceptible TB. The efficacy of treatment for MDR-TB is poorer than that for drug-susceptible TB. The selection of drugs in MDR-TB is based on previous treatment history, drug susceptibility results, and TB drug resistance patterns in the each region. Recent World Health Organization guidelines recommend the use of least 4 second-line drugs (a newer fluoroquinolone, an injectable agent, prothionamide, and cycloserine or para-aminosalicylic acid) in addition to pyrazinamide. The kanamycin is the initial choice of injectable durgs, and newer fluoroquinolones include levofloxacin and moxifloxacin. For MDR-TB, especially cases that are extensively drug-resistant, group 5 drugs such as linezolid, clofazimine, and amoxicillin/clavulanate need to be included. New agents with novel mechanisms of action that can be given for shorter durations (9-12 months) for MDR-TB are under investigation.
|
|
|
KEYWORD
|
|
|
Tuberculosis, Multidrug-resistant, Therapeutics, Extensively drug-resistant tuberculosis
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|